Clinical trials: Growth Delay
Foetal Growth Problem, Small for Gestational Age
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
This trial is conducted in Europe. The aim of this trial is to assess and compare the efficacy and safety of two dose levels of somatropin over a long period (till final height is reached).
- Trial name
- NCT01697644
- Testing
- somatropin
- Where
- 2 sites in Netherlands
- Volunteers
- 75 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease, Chronic Renal Insufficiency
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
This trial is conducted in Europe. Objective(s): To evaluate the effect of human growth hormone on infants aged 1 to 2 years with chronic renal insufficiency (CRI) and growth retardation despite an adequate dietary intake.
- Trial name
- NCT00184769
- Testing
- somatropin
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Pharmacokinetic Evaluation of Testosterone Gel (1%)
Measure and evaluate the level of testosterone in blood, and determine the safety and tolerability following daily applications of testosterone gel.
- Trial name
- NCT00193700
- Testing
- Testosterone Gel (1%)
- Where
- 9 sites in United States
- Sponsor
- Solvay Pharmaceuticals
Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
This study is to observe efficacy and safety after T-Gel 1% treatment in delayed puberty adolescents. Subjects who complete this trial may enter a 3 month extension study (UMD-01-090E).
- Trial name
- NCT00193661
- Testing
- Testosterone Gel (1%)
- Where
- 19 sites in United States
- Sponsor
- Solvay Pharmaceuticals
Growth Disorders, Intrauterine Growth Retardation
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation
- Trial name
- NCT01073605
- Testing
- Genotonorm
- Where
- 31 sites in France
- Volunteers
- 208 people
- Sponsor
- Pfizer
Foetal Growth Problem, Small for Gestational Age
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.
- Trial name
- NCT01734447
- Testing
- somatropin
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Novo Nordisk A/S
Children Born With Serious Intra-uterine Growth Retardation
Saizen in Intra-uterine Growth Retardation
Study of safety of Saizen® in children born with serious intra-uterine growth retardation (IUGR) treated to final height. An open, phase III study involving 17 centers in France.
- Trial name
- NCT01400698
- Testing
- Saizen® A, Saizen® B, Observation only
- Volunteers
- 91 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Fetal Growth Retardation
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
To estimate the percentage of children with serum IGF-1 > 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.
- Trial name
- NCT00174252
- Testing
- Genotonorm (Somatropin)
- Where
- 22 sites in France
- Volunteers
- 57 people
- Sponsor
- Pfizer
Fetal Growth Retardation
MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children
1. To test for equivalence in terms of catch-up growth between the 2 therapeutic regimens 2. To specify the best period of treatment 3. To assess the efficacy of treatment based on final adult height of these children
- Trial name
- NCT00452491
- Testing
- somatropin
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Sanofi
Growth Hormone Deficiency, Growth Retardation
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
To assess the effect of long-term treatment by Genotonorm on linear growth
- Trial name
- NCT00174278
- Testing
- Somatropin
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Pfizer
Insulin-like Growth Factor-1 Deficiency
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
IGF-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in response to another hormone called growth hormone. Growth Hormone is produced by a small gland at the base of the brain (the pituitary).
- Trial name
- NCT00572156
- Testing
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Ipsen
Endocrine System Diseases
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
To evaluate the effect of increasing the growth hormone dose on the statural response To assess the value of early treatment during the course of arthritic disease by comparing the height acquired in the medium term by children…
- Trial name
- NCT00174291
- Testing
- Somatropin
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Pfizer
Growth Disorders
Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome
Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally with the aid of an electronic…
- Trial name
- RAZANT (NCT03274973)
- Testing
- Zomacton
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
Spasticity, Muscle, Microcephaly
Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss.
- Conditions
- Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation
- Trial name
- NCT05518188
- Testing
- MELPIDA
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Elpida Therapeutics SPC
Growth Hormone Deficiency
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH…
- Trial name
- NCT00163189
- Testing
- Somatropin
- Where
- 19 sites in France
- Volunteers
- 98 people
- Sponsor
- Pfizer
Endocrine System Diseases
Growth Retardation In Children With Special Pathological Conditions Or Disease
To show an increase in annual growth rate 3 years after Visit 2. Annual growth rate in standard deviation (SD) after 3 years will be compared to growth rate before the start of GH treatment.
- Trial name
- NCT00163215
- Testing
- Somatropin
- Where
- 18 sites in France
- Volunteers
- 46 people
- Sponsor
- Pfizer
Growth Retardation
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period 2.
- Trial name
- NCT03290235
- Testing
- PEG-somatropin
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.